从签约到解约仅28天！因客观情况发生变化，再升科技3.44亿元股份转让案“流产”

Core Viewpoint - The announcement from Zaiseng Technology (再升科技) regarding the termination of the share transfer agreement with Zhongrong Huaxin International Biotechnology (中融华信) raises questions about the underlying reasons for this abrupt decision, which occurred just 28 days after the initial agreement was signed [2][3]. Group 1: Share Transfer Agreement - On December 8, 2025, Zaiseng Technology's controlling shareholder, Guo Mao, signed a share transfer agreement to sell 6.04% of the company's shares to Zhongrong Huaxin for a total of 344 million yuan, at a price of 5.53 yuan per share [2][3]. - The agreement was seen as a strategic move to optimize the company's equity structure and introduce external capital [3]. - The termination of the agreement was attributed to "changes in objective circumstances," although specific details were not disclosed [3][4]. Group 2: Financial Performance - Zaiseng Technology reported a 10.11% year-on-year decline in revenue for the first three quarters of 2025, totaling 985 million yuan, and a 10.59% decrease in net profit to 81.25 million yuan [5]. - Despite the overall decline, the company achieved a significant quarterly net profit increase of 42.42% in Q3 2025, amounting to 20.97 million yuan, driven by cost reduction and new product development [5]. - The company's cash flow situation improved markedly, with net cash flow from operating activities reaching 260 million yuan, a 60.51% increase year-on-year [5].